This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Masimo (MASI) Boosts O3 Platform With Three New Indices
by Zacks Equity Research
Masimo (MASI) announced the development of three additional indices for O3 Regional Oximetry, thereby improving the O3 platform.
Here's Why Investors Should Retain Accuray (ARAY) Stock Now
by Zacks Equity Research
Accuray (ARAY) slashes fiscal 2020 revenue guidance owing to tariffs in China.
Masimo (MASI) Introduces Pathway, Boosts Patient Monitoring
by Zacks Equity Research
Masimo's (MASI) new feature, Pathway, is likely to help clinicians simplify their workflow associated with newborn resuscitation, thereby improving patient monitoring.
Is Masimo (MASI) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (MASI) Outperforming Other Medical Stocks This Year?
HealthEquity (HQY) Earnings & Revenues Beat Estimates in Q2
by Zacks Equity Research
HealthEquity (HQY) gains from solid segmental contributions in second-quarter fiscal 2020.
HealthEquity Acquires WageWorks, To Make Notable Investments
by Zacks Equity Research
HealthEquity (HQY) expects to complete its $80-100 million investment program within 24-36 months from now.
Cooper Companies (COO) Q3 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Cooper Companies (COO) gains from solid segmental contributions in fiscal Q3.
Varian's ProBeam Compact System Picked by University of Miami
by Zacks Equity Research
Varian (VAR) sees notable developments in its Proton Solutions business of late.
DexCom (DXCM) Scales 52-Week High: What's Driving the Stock?
by Zacks Equity Research
DexCom (DXCM) has various favorable factors to maintain the current high.
Has Masimo (MASI) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (MASI) Outperforming Other Medical Stocks This Year?
Is Masimo (MASI) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (MASI) Outperforming Other Medical Stocks This Year?
DexCom (DXCM) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
DexCom (DXCM) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Masimo (MASI) Earnings and Revenues Beat Estimates in Q2
by Zacks Equity Research
Buoyed by a solid second quarter, Masimo (MASI) raises its 2019 guidance.
Masimo (MASI) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 4.11% and 3.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Earnings Roster for Jul 31: MCK, HOLX & More
by Zacks Equity Research
Solid growth in emerging markets is expected to be an added positive this earnings season.
Masimo (MASI) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Masimo's (MASI) recent developments likely to show on second-quarter results.
Masimo (MASI) Q2 Earnings Preview: What's in the Cards?
by Zacks Equity Research
Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Masimo (MASI) Hits a 52-Week High on Solid Growth Drivers
by Zacks Equity Research
Masimo (MASI) gains from expansion of product portfolio and recent regulatory approvals.
Here's Why You Should Add Bruker (BRKR) to Your Portfolio
by Zacks Equity Research
Investor confidence in Bruker stock (BRKR) is high on substantial potential of MALDI Biotyper.
Here's Why You Should Buy Masimo (MASI) Stock Right Now
by Zacks Equity Research
Masimo (MASI) receives FDA clearance for its O3 Regional Oximetry for utilization on neonatal and infant patients.
Near-Term Outlook for Medical Instruments Industry Bleak
by Urmimala Biswas
Complex regulatory hurdles come in the way of any infrastructural or technology growth in the Medical Instruments space.
DaVita Divests DMG to Optum, Boosts Kidney Care Services
by Zacks Equity Research
The divestment of DMG boosts DaVita's (DVA) core Kidney Care business.
Here's Why You Should Hold PerkinElmer (PKI) Stock for Now
by Zacks Equity Research
PerkinElmer (PKI) raises earnings per share guidance for 2019.
Merit Medical Acquires Brightwater Medical for $35 Million
by Zacks Equity Research
The Brightwater Medical-acquisition broadens Merit Medical's (MMSI) product offerings.
Here's Why You Should Hold Baxter International (BAX) for Now
by Zacks Equity Research
Baxter (BAX) expects its bottom line to rise in the second quarter of 2019, courtesy to Renal Care and Clinical Nutrition businesses.